I watched enterprises buy AI that solved the wrong problem. So I left Dell and built a startup to fix it

The article argues that coordinated AI could cut a drug-coverage review process from 60-90 days and about $100,000 per drug to 4-8 hours, with direct labor costs down 97%. It highlights the administrative burden in healthcare, including 600 nurses at one enterprise focused on prior authorization and the AMA’s finding that prior authorization takes 13 hours per week and delays care for 93% of physicians. The piece is primarily a strategic commentary on AI governance in regulated industries rather than a company-specific market catalyst.

Analysis

The durable winner here is not the model layer; it is the workflow-orchestration layer that can sit above fragmented, regulated decision chains and produce an audit trail. That creates a longer runway for governance, controls, and human-in-the-loop software than for pure agent providers, because the first wave of spend will come from enterprises trying to avoid compliance blowups and failed pilots rather than from chasing autonomy for its own sake. In healthcare, that should pull budget away from generic horizontal AI tools and toward vertical platforms with embedded policy logic, document provenance, and integration into claims/prior-auth systems.

The second-order effect is that administrative labor reduction is only part of the P&L math; the bigger near-term lever is avoided leakage and faster cycle times. In payers, cutting decision latency compresses hospital admission risk, reduces escalation from interrupted therapies, and can improve member retention by reducing friction, which matters more than the direct labor savings. That also implies competitors built on human workflow outsourcing are vulnerable: if AI orchestration proves auditable, the economic moat moves from headcount scale to data access, policy content, and distribution into payer/provider systems.

The key risk is adoption timing. Most enterprises will not rip-and-replace; they will pilot for 6-18 months, stall on governance, then re-architect after a compliance event or cost overrun forces action. In the near term, that makes the market prone to overprice “agent counts” and underprice control planes, but the underlying buyers will be conservative, so revenue inflection could lag product announcements by multiple quarters. A reversal would come if regulators or plaintiffs’ attorneys make agentic decisions materially more expensive to defend than human ones, which would shift demand even faster toward auditable orchestration.

Contrarian read: the market may be too skeptical on enterprise AI broadly, but too optimistic on standalone agent vendors specifically. The article’s math argues that value comes from eliminating sequential handoffs, not from maximizing autonomy, so the best setups are likely software platforms that can standardize exception handling across regulated workflows. In other words, the prize is not ‘more AI workers’; it is the operating system that decides when AI is allowed to work and when a specialist must intervene.

Key Decisions for Investors

• Long IT, short high-beta standalone AI infrastructure/agent names over 3-6 months: the thesis is that governance, audit, and workflow software monetize first while agent-only vendors face slower conversion and higher cancellation risk.
• Add to DELL on any pullback over the next 1-2 quarters as a systems/integration beneficiary of enterprise AI re-platforming; risk/reward improves if buyers shift from pilot spend to operational rollout, but the position should be sized modestly because per-ticker signal is neutral.
• Initiate a basket long in regulated-workflow software and services versus short generic horizontal AI application exposure: the relative winner should be firms selling compliance, traceability, and process orchestration rather than model novelty.
• Buy medium-dated call spreads on a leading governance/ITSM platform if weakness follows another round of weak pilot data; the trade is for a 6-12 month rerating as enterprises fund controls after pilot failure rather than additional agents.
• Avoid chasing pure-play agent beneficiaries until there is evidence of repeatable revenue from production deployments; consensus is still overestimating the speed of autonomous adoption versus the slower but more durable control-plane cycle.